Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS

Journal of the Neurological Sciences

Volumn 318, Issue 1-2, 2012, Pages 119-124

  Balcer, Laura J ^a   Galetta, Steven L ^a   Polman, Chris H ^b   Eggenberger, Eric ^c   Calabresi, Peter A ^d   Zhang, Annie ^e   Scanlon, James V ^e   Hyde, Robert ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c East Lansing   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BIOGEN   (United States)

Author keywords

Low contrast letter acuity; Multiple sclerosis (MS); Natalizumab; Vision

Indexed keywords

NATALIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; BINOCULAR VISION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LOW CONTRAST LETTER ACUITY; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; VISUAL ACUITY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VISION DISORDERS; YOUNG ADULT;

EID: 84861616052     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.03.009     Document Type: Article

References (40)

1. J. Graves, and L.J. Balcer Eye disorders in patients with multiple sclerosis: natural history and management Clin Ophthalmol 4 2010 1409 1422
2. E.M. Frohman, T.C. Frohman, D.S. Zee, R. McColl, and S. Galetta The neuro-ophthalmology of multiple sclerosis Lancet Neurol 4 2005 111 121
3. E.M. Mowry, M.J. Loguidice, and A.B. Daniels Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity J Neurol Neurosurg Psychiatry 80 2009 767 772
4. B.A. Raphael, K.M. Galetta, and D.A. Jacobs Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25 Am J Ophthalmol 142 2006 1026 1035
5. S.L. Ma, J.A. Shea, and S.L. Galetta Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire Am J Ophthalmol 133 2002 686 692
6. J. Noble, F. Forooghian, M. Sproule, C. Westall, and P. O'Connor Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients Am J Ophthalmol 142 2006 464 468
7. D. Miller, R.A. Rudick, and M. Hutchinson Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life Neurology 74 Suppl. 3 2010 S24 S35
8. R.A. Rudick, D. Miller, S. Hass for the AFFIRM and SENTINEL Investigators Health-related quality of life in multiple sclerosis: effects of natalizumab Ann Neurol 62 2007 335 346
9. C. Heesen, J. Böhm, C. Reich, J. Kasper, M. Goebel, and S.M. Gold Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable Mult Scler 14 2008 988 991
10. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
11. R. Rudick, J. Antel, and C. Confavreux Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force Ann Neurol 42 1997 379 382
12. G.R. Cutter, M.L. Baier, and R.A. Rudick Development of a multiple sclerosis functional composite as a clinical trial outcome measure Brain 122 1999 871 882
13. C.H. Polman, and R.A. Rudick The Multiple Sclerosis Functional Composite: a clinically-meaningful measure of disability Neurology 74 Suppl. 3 2010 S8 S15
14. L.J. Balcer, S.L. Galetta, and P.A. Calabresi Natalizumab reduces visual loss in patients with relapsing multiple sclerosis Neurology 68 2007 1299 1304
15. L.J. Balcer, M.L. Baier, and V.S. Pelak New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis Mult Scler 6 2000 163 171
16. L.J. Balcer, M.L. Baier, and J.A. Cohen Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite Neurology 61 2003 1367 1373
17. M.L. Baier, G.R. Cutter, and R.A. Rudick Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis Neurology 64 2005 992 995
18. L.J. Balcer, and E.M. Frohman Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity Neurology 74 Suppl. 3 2010 S16 S23
19. J.B. Fisher, D.A. Jacobs, and C.E. Markowitz Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis Ophthalmology 113 2006 324 332
20. L.S. Talman, E.R. Bisker, and D.J. Sackel Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis Ann Neurol 67 2010 749 760
21. B.M. Burkholder, B. Osborne, and M.J. Loguidice Macular volume by optical coherence tomography as a measure of neuronal loss in multiple sclerosis Arch Neurol 66 2009 1366 1372
22. G.F. Wu, E.D. Schwartz, and T. Lei Relation of vision to global and regional brain MRI in multiple sclerosis Neurology 69 2007 2128 2135
23. B. Weinstock-Guttman, M. Baier, and R. Stockton Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis Mult Scler 9 2003 529 534
24. Galetta, S.L.; Balcer, L.J.; Polman, C.H.; et al., Low-contrast letter acuity and its association with EDSS, quality of life, and MRI measures in the AFFIRM trial. Mult Scler 2010. In: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Gothenburg, Sweden. (2010).
25. F. Munschauer, G. Giovannoni, and F. Lublin Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability Mult Scler 14 2008 S167 S168
26. E. Havrdova, S. Galetta, and M. Hutchinson Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol 8 2009 254 260
27. R.A. Rudick, W.H. Stuart, and P.A. Calabresi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923
28. C.H. Polman, P.W. O'Connor, and E. Havrdova A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
29. R. Klein, B.E.K. Klein, S.E. Moss, and D. DeMets Inter-observer variation in refraction and visual acuity measurement using a standardized protocol Ophthalmology 90 1983 1357 1359
30. Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): Manual of Operations [online]. Available at: www.med.upenn.edu/cpob/ studies/documents/MOP-JULY-2000.EP.pdf 2000
31. S.P. Azen, R. Varma, S. Preston-Martin, M. Ying-Lai, D. Globe, and S. Hahn Binocular visual acuity summation and inhibition in an ocular epidemiological study: the Los Angeles Latino Eye Study Invest Ophthalmol Vis Sci 43 2002 1742 1748
32. G.S. Rubin, B. Munoz, K. Bandeen-Roche, and S.K. West Monocular versus binocular visual acuity as measures of vision impairment and predictors of visual disability Invest Ophthalmol Vis Sci 41 2000 3327 3334
33. S.L. Pineles, E.E. Birch, and L.S. Talman One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis Am J Ophthalmol 152 2011 133 140
34. D.A. Rosser, S.N. Cousens, and I.E. Murdoch How sensitive to clinical change are ETDRS and logMAR visual acuity measurements? Invest Ophthalmol Vis Sci 44 2003 3278 3281
35. R.W. Beck, M.G. Maguire, N.M. Bressler, A.R. Glassman, A.S. Lindblad, and F.L. Ferris Visual acuity as an outcome measure in clinical trials of retinal diseases Ophthalmology 114 2007 1804 1809
36. F.L. Ferris, A. Kassoff, G.H. Bresnick, and I. Bailey New visual acuity charts for clinical research Am J Ophthalmol 94 1982 91 96
37. D.B. Clifford, A. De Luca, D.M. Simpson, G. Arendt, G. Giovannoni, and A. Nath Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 2010 438 446
38. L. Gorelik, M. Lerner, and S. Bixler Anti-JC virus antibodies: implications for PML risk stratification Ann Neurol 68 2010 295 303
39. Sandrock A, Hotermans C, Richman S, et al. Risk stratification for progressive multifocal leukoencephalopathy in multiple sclerosis patients using natalizumab. Presented at: ENS; May 28-31, 2011; Lisbon, Portugal. O212.
40. Biogen Idec Medical Information Website. Accessed on February 14, 2012. Available at https://medinfo.biogenidec.com/.